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T HE temptation to indulge in reminis-
cences would be greater if the story of 
transplantation had gone to the glorious 
climax and denouement that seemed so immi-
nent a decade and a half ago. Sixteen years 
ago (September 6, 1963) many of the people 
here today met in Washington, D.C. at the 
National Research Council to consider what 
seemed to be electrifying recent events in 
transplantation. It seemed certain that a new 
clinical specialty was at hand in which there 
would be widespread replacement not only of 
kidneys but of other organs. Within the 
preceding few months, the first efforts had 
been made in Denver and in Boston to trans-
plant an extrarenal vital organ, namely, the 
liver. Although the recipients had died, it was 
predicted (and correctly as it turned out) that 
success would not be far off. 
However, the expectations of 1963 have not 
been fully met. As we all know, nostalgia has 
the power and magic to blur reality and to 
make gray things bright. Yet, I doubt if many 
here would claim that transplantation today 
offers a safe and predictable service to a much 
greater extent than it did in the 1960s. To the 
degree that this is recognized, perhaps it is 
justifiable to glance back over our shoulders 
and describe some of the problems of human 
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organ transplantation as they were perceived 
at the time of our first clinical trials 18 years 
ago and subsequently. I was not involved in 
transplantation until 1958, 4 years before the 
first consistent successes began to be obtained 
with kidney transplantation. I have reviewed 
the importance of these years preceding 
1962.' The central role of the workers at the 
Peter Bent Brigham Hospital can be appre-
ciated from the catalogue of landmarks in 
renal transplantation provided by Groth of 
Stockholm after his study of the written 
record and after discussions with most of the 
workers actually involved in the work done 
from 1950 onward. 2 
It became my personal opportunity to 
participate in the great advances in kidney 
transplantation starting in 1962 and to apply 
what was being learned with the kidney to 
transplantation of the liver. The interorgan 
transfer of such information was natural since 
the liver was the means of my first involve-
ment in transplantation. In the summer of 
1958, while at Northwestern University in 
Chicago, I developed a new method for one-
stage hepatectomy in dogs. I appreciated how 
easy it would be to replace the liver with a 
graft using a temporary portacaval shunt with 
or without an external bypass to decompress 
the blocked splanchnic and systemic circula-
tions. At about this time, I had decided to 
remain in university work in preference to 
entering private practice and had spent 
several weeks in the medical library trying to 
decide on some broad area of research in 
which to make an investment. 
Transplantation seemed a worthwhile chal-
lenge, partly because of the deeply pessimistic 
attitudes that prevailed about the prospects of 
clinical organ transplantation in any except 
the most unusual cases, such as those involv-
ing fraternal twins. Transplantation of the 
liver was especially appealing at that time 
because of its technical challenge. 
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Another factor that gave the liver special 
interest was speculation by Dr. Jack Cannon 
of Los Angeles that the liver played an impor-
tant role in rejection. Because of this, 
Cannon, who was the first to attempt liver 
replacement,3 apparently hoped that a 
hepatic homograft might suffer a different 
fate from that of other transplanted tissues, 
since it presumably would not contribute to its 
own repudiation. Although the liver was 
rejected, it has seemed to be less susceptible 
to rejection than any other major organ but 
for reasons that are still not understood.4 By 
mid-1958, work on orthotopic liver transplan-
tation in dogs had also begun in the Harvard 
laboratories of Francis D. Moore. The studies 
from the Boston5 and Chicag06,7 laboratories 
showed the technical feasibility of orthotopic 
liver transplantation, but they held no clue to 
the prevention of rejection. As reviewed else-
where, I such clues depended on different 
kinds of laboratory investigation that showed 
that steroids, 6-mercaptopurine, and azathio-
prine were immunosuppressive. 
THE PROTOTYPE KIDNEY MODEL 
The kind of laboratory research with 
steroids, 6-mercaptopurine and azathioprine 
mentioned above was applicable in one way or 
another to organ replacement in man, but the 
connection was not straightforward. In occa-
sional dogs a protracted life proved possible 
after renal transplantation with the use of 
steroids,8 6-mercaptopurine,9 or azathio-
prine'0- '2 as the sole immunosuppressive 
treatment. In man occasional similar suc-
cesses were also achieved solely with 6-
mercaptopurine or azathioprine, as summa-
rized by Groth.2 Nevertheless, the consistency 
with which really long-term survival was 
obtained was poor. The obvious reason was 
that complete control of rejection was rarely 
achieved. 
Thus, both the animal data and the initial 
clinical experience discouraged further trials, 
even with kidney transplantation. The most 
important development that made immuno-
suppression practical was the discovery of the 
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way in which azathioprine and prednisone 
could be advantageously used together. There 
were essentially no preceding laboratory data 
to indicate that the benefit with this now 
universally accepted combination of agents 
would be as great as proved to be the case. 
Indeed, the first publication on experience in 
animals '3 was a belated confirmation of the 
far more convincing observations already 
made in humans. 14-17 
Standardization of combined azathioprine-
steroid therapy cannot be ascribed to any 
single authority or transplantation group. 
What is clear is that by early 1963 the two 
drugs were being used together in one way or 
another and with varying degrees of convic-
tion about their synergism for the prevention 
or reversal of renal homograft rejection in at 
least one British '4 and three American 
centers. 15-\7 Since then, variations of these 
regimens have been adopted throughout the 
world. 
The reversibility of rejection in these 
patients was only one of the features that 
established the clinical feasibility of organ 
transplantation. The quantities of adrenal 
corticosteroids necessary to achieve reversal 
were often too large to be compatible with 
long survival of the recipient if continued 
indefinitely. Fortunately, another event of 
equal practical importance transpired coinci-
dentally with the reversal of rejection or 
shortly afterward. With the passage of time, 
the need for intensive therapy usually dimin-
ished both in patients who did and especially 
in those who did not pass through a clinically 
evident rejection. 
There was little reason to doubt that a 
homograft became more or less privileged if it 
could be kept alive through the initial 
onslaught of rejection. This fact strongly 
influenced the way in which newer thera-
peutic agents such as heterologous antilym-
phocyte globulin (ALG) were used clinical-
ly,18 and it was a prime stimulus for the 
extension of transplantation techniques to 
organs other than the kidney in which both 
reversal of rejection and "adaptation" proved 
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not to be very different from what they were 
with the kidney. 
THE LIVER TRIALS 
Looking back at the Colorado scene of the 
early 1960s, it was inevitable that transplan-
tation of the liver would be performed. Opti-
mism was high because of the success of 
multiple drug immunosuppression in control-
ling renal homograft rejection. The assump-
tion was made that the same therapy would 
be applicable for other organs, a view that 
was proved correct both in animals and man.4 
Finally, the ability to carry out liver trans-
plantation had been assiduously developed in 
research involving hundreds of dogs during 
the preceding 5 years and was known to be 
within our technical capability. Thus, a policy 
decision was made in early 1963 to proceed 
with orthotopic liver transplantation, an oper-
ation that requires removal of the diseased 
native organ and its replacement with a 
cadaveric graft. 
The first four attempts were made in 1963 
on March I, May 5, June 24, and July 16. A 
fifth patient was treated by Francis Moore in 
Boston on September 16, 1963, followed by 
another in Denver on October 4, 1963 (all 
early cases in Denver and elsewhere are cata-
logued in Starzl,4 pp 503-532). 
Our first recipient bled to death during the 
operation; the other four first Denver patients 
survived operation but died from 6.5 to 23 
days later. Success was nearly achieved in 
some of these cases. 19 For example, our 
second patient, a 48-year-old male with cir-
rhosis and a hepatoma, was in remarkably 
good condition postoperatively. He died 22 
days later of systemic and pulmonary infec-
tion. At autopsy there were no serious compli-
cations in the abdominal cavity. The liver had 
no unequivocal findings of rejection. Biliary 
duct reconstruction with choledochocholedo-
chostomy over a T-tube was satisfactory. 
Portions of both lungs were necrotic. The 
pulmonary arteries contained multiple old 
clots. Apparently, these were deposited at the 
time of operation from a plastic bypass tubing 
that had been used to return blood from the 
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vena caval and splanchnic venous pools while 
these systems were obstructed during the 
intraoperative anhepatic phase. Ironically, it 
was later proved that such temporary 
bypasses are unnecessary because of the well-
developed venous collaterais in end-stage liver 
disease. 
The series of consecutive early failures 
caused a moratorium of 3 years to be declared 
on further cases. Only one more patient was 
treated at our center until the summer of 
1967. The justification to then start another 
series came from experience with the triple 
drug immunosuppressive program (including 
ALG) which by then seemed to be helping the 
kidney recipients.4.18 On July 23, 1967, the 
chance presented to treat a 1.5-year-old girl 
who had a hepatoma. She lived through the 
operation of liver replacement and for 13 
months afterward before finally dying of 
widespread tumor metastases. Each of the 
next 8 recipients lived for at least 2 months 
postoperatively, and 3 of these 8 lived for 
more than 1 year with the longest survival of 
29 months and 16 days. 
The first 25 liver recipients in the Colorado 
series eventually provided the experience for a 
text of liver transplantation.4 Five of these 25 
patients lived a year or more. The feasibility 
stage of human liver transplantation had been 
passed, but with I-year mortality of 80%, 
widespread exploitation of the procedure was 
a long way off. 
Nor was there a quantum improvement in 
the succeeding 7 years. The patients surviving 
for I year in the second, third, and fourth 
groups of 25 patients each were only 6, 8, and 
9, respectively. However, one of these recip-
ients is now 10 years postoperative and a total 
of 14 have lived more than 5 years; 13 of these 
14 are still alive. 
During a sabbatical leave in 1975 and 
1976, I had an opportunity to live in London 
and work with Professor K. A. Porter, the 
grcat English pathologist who had earlier 
worked in Boston with Gustave Dammin and 
with whom I had collaborated continuously 
since 1963. Together, we reviewed the first 93 
cases of orthotopic liver transplantation and 
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tried to recatalogue the main reasons for 
failure. Our conclusions were (I) uncon-
trolled rejection was a relatively uncommon 
cause of mortality; (2) technical mistakes and 
mechanical problems with the homografts 
accounted for the greatest numbers of deaths; 
and (3) if the complications were of duct 
reconstruction, they frequently caused un-
trea table infections. 
Better management guidelines were devel-
oped based on more accurate postoperative 
diagnosis with emphasis on frequent needle 
biopsies and transhepatic cholangiography, 
avoidance of overimmunosuppression while 
using the triple drug therapy, and better tech-
nical performance at the original operation. 
The most fundamental technical adjustment 
was to perform biliary duct reconstruction 
with choledochocholedochostomy over a T-
tube stent, or by anastomosis of a Roux-en- Y 
jejunal limb to the graft gallbladder or 
common duct. The various changes were 
completed and standardized by late spring 
1976. 
In the ensuing 2 years, the I-year survival 
in 30 consecutive patients rose to 50%/° and 
I 3 of these I 5 I-year survivors are still alive 
now after 2-3.5 years. The same improve-
ment in recent results has been noted also by 
CaIne and Williams working in England.2l 
Unfortunately, it does not now seem that a 
further increase in survival will be possible 
without some fundamental improvement in 
immunosuppression. 
PHYSIOLOGIC FALL-OUT 
One of the major by-products of liver trans-
plantation has been new insight about the 
effect of portal blood and its so-called hepato-
trophic constituents on liver structure, func-
tion, and the capacity for regeneration. This 
new area of research22 was opened during 
inquiries into the optimum means of revascu-
larizing auxiliary liver homografts while leav-
ing the native organ in placeY The essence of 
the portal hepatotrophic concept is that the 
liver is controlled or influenced profoundly by 
hormones coming from the venous effluent of 
splanchnic viscera into the portal vein. Insulin 
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is the most influential of these hormonal 
factors, although not the only one. From a 
practical point of view and as it relates to 
transplantation, the implication is that the 
portal vein of an auxiliary liver should be 
supplied with splanchnic venous blood if it is 
to have an optimal chance of survival. 
Auxiliary liver transplantation was first 
attempted in humans by Absolon et al. 24 and 
was also given a brief trial at our center.4 The 
only person to definitely benefit from this 
procedure so far has been a child cared for by 
Dr. Joseph Fortner of New York who is now 6 
years after auxiliary transplantation for 
biliary atresia. 25 We have not performed this 
operation for several years. 
OUR DEBT TO THE BRIGHAM 
It is fitting today to reflect on the remark-
able influence that came from Harvard 
University and the Peter Bent Brigham 
Hospital in the beginning of clinical organ 
transplantation. In any scholarly summary of 
the publications from that era can be found 
the names of Dave Hume, Joe Murray, John 
Merrill, Roy Caine, Gus Dammin, and 
numerous others of the Brigham alma mater 
who are gathered here today. Even vineyard 
workers like myself who did not visit Harvard 
until years later were directly affected by the 
intellectual emanations from the Mecca. 
What may not be so evident from the 
written record was the omnipresence of Fran-
cis D. Moore. I am sure that I was not the 
only one who saw Franny as a spiritual leader 
to whom we could turn in difficult times. In 
addition to his sponsorship of the Brigham 
kidney program, Dr. Moore involved himself 
in laborious and often heartbreaking labora-
tory research that made liver replacement a 
respectable clinical possibility. Furthermore, 
Franny's generosity to and support of younger 
colleagues played an indispensable role in 
making the clinical trial of liver transplanta-
tion in Denver and in Cambridge, England, 
acceptable to our peers. 
I have often wondered how many of us 
would have been destroyed by our own efforts 
had it not been for Franny Moore. 
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